Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Bayer Aktiengesellschaft patents


Recent patent applications related to Bayer Aktiengesellschaft. Bayer Aktiengesellschaft is listed as an Agent/Assignee. Note: Bayer Aktiengesellschaft may have other listings under different names/spellings. We're not affiliated with Bayer Aktiengesellschaft, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "B" | Bayer Aktiengesellschaft-related inventors


Modular system and process for the continuous, microbe-reduced production and/or processing of a product

The invention provides a method for the continuous, microbe-reduced production and/or processing of a biopharmaceutical, biological macromolecular product from a heterogeneous cell culture-fluid mixture, comprising the steps of: (a) providing a particle-free fluid from a heterogeneous cell culture-fluid mixture containing the product, in the form of a product stream, (b) at least one filtration, providing a filtrate, (c) at least two chromatography steps for purifying the product, (d) at least one virus depletion, (e) at least one ultrafiltration and/or at least one diafiltration of the product stream of steps (b), (c) and/or (d), characterized in that the at least two chromatography steps from (c) comprise a purification via at least two chromatography columns and/or membrane adsorbers in each case and that the process is carried out in a closed and modular manner the invention further provides a corresponding modular system for carrying out said method.. . ... Bayer Aktiengesellschaft

Process control system for control and regulation of a modular plant for the production of biopharmaceutical and biological macromolecular products

The invention relates to a modular production plant for continuous production and/or preparation of biopharmaceutical products, a computer-implemented method for process control of the modular plant for production of biopharmaceutical and biological macromolecular products, in particular of proteins, e.g. Monoclonal antibodies, vaccines, nucleic acids such as dna, rna and plasmids and derivatives thereof.. ... Bayer Aktiengesellschaft

1,3-thiazol-2-yl substituted benzamides

. . The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (i) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Aktiengesellschaft

Continuous process and apparatus for purifying so2-containing gases

The invention relates to a continuous process for purifying a gas containing 60-99 percent so2 (sulfur dioxide) by volume and 1 to 40 percent steam by volume, followed by synthesis of so3 (sulfur trioxide) without first drying the gas, and to an apparatus for carrying out said method.. . ... Bayer Aktiengesellschaft

1,3-thiazol-2-yl substituted benzamides

The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (i) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Aktiengesellschaft

1,3-thiazol-2-yl substituted benzamides

The present invention relates to 1,3-thiazol-2-yl substituted benzamide compounds of general formula (i) as described and defined herein, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neurogenic disorder, as a sole agent or in combination with other active ingredients.. . ... Bayer Aktiengesellschaft

Device and method for determining the action of active ingredients on nematodes and other organisms in aqueous tests

The invention relates to a device (1) and a method for determining the action of active ingredients on nematodes and other organisms in aqueous tests. The device (1) according to the invention comprises a holder (13) for a cell culture plate (30) having multiple wells (31) in which the nematodes can be filled with the active ingredients, said cell culture plate (30) having a bottom side (33), a top side (32) and also side walls extending between bottom side (33) and top side (32), a camera (11) which is used to record images of preferably the bottom side (33) of the cell culture plate (30), a lighting mechanism (14) having at least a first light source (15) which illuminates the cell culture plate (30), there being arranged between the first light source (15) and a first side wall (34) of the cell culture plate (30) in the installed state a first optical unit which directs the light of the first light source (15) through the first side wall (34) in the direction of the bottom side (33) of the cell culture plate (30). ... Bayer Aktiengesellschaft

Genotype- or phenotype-based drug formulation

The invention relates to a combination of two or more pharmaceutically active substances, of which at least one is a metabolic product (“metabolite”) of the other (“parent substance”), wherein in particular the dosages thereof are selected such that genotypically or phenotypically related variability in the conversion of the parent substance to the metabolite in particular individuals is compensated for.. . ... Bayer Aktiengesellschaft

Genotype- or phenotype-based drug formulations

The invention relates to a combination of two or more pharmaceutically active substances, of which at least one is a metabolic product (“metabolite”) of the other (“parent substance”), wherein in particular the dosages thereof are selected such that genotypically or phenotypically related variability in the conversion of the parent substance to the metabolite in particular individuals is compensated for.. . ... Bayer Aktiengesellschaft

Method for phosgenating compounds containing hydroxyl, thiol, amino and/or formamide groups

The invention relates to a method particularly for reacting phosgene with compounds that contain hydroxyl, thiol, amino and/or formamide groups, comprising the steps of: (i) providing a reactor which has a first reaction chamber (300, 310, 320, 330, 340, 350) and a second reaction chamber (200, 210, 220, 230, 240, 250, 260), the first and the second reaction chambers being separated from one another by means of a porous carbon membrane (100, 110, 120, 130, 140, 150); (ii) providing carbon monoxide and chlorine in the first reaction chamber; and simultaneously (iii) providing a compound containing hydroxyl, thiol, amino and/or formamide groups in the second reaction chamber. The porous carbon membrane is configured to catalyse the reaction of carbon monoxide and chlorine to obtain phosgene, and to allow this formed phosgene to pass into the second reaction chamber. ... Bayer Aktiengesellschaft

Method for the phosgenation of compounds comprising hydroxyl, thiol, amino and/or formamide groups

A method of reacting a first compound with a second compound, wherein the first compound has a ghs hazard identification of ghs06 and is obtainable from the reaction of at least one first fluid precursor compound and one second fluid precursor compound and wherein the second compound is capable of a chemical reaction with the first compound is provided. . ... Bayer Aktiengesellschaft

Earthable flexible intermediate bulk container

The application relates to an earthable flexible intermediate bulk container comprising a container 1 made of a flexible material, which has a dissipative or conductive grid of conductive threads 5, or alternatively is dissipative or conductive over the full surface area, and at least one carrying strap 2 connected to the container 1 by means of a carrying seam 3, characterized in that at least one carrying strap 2 is provided over the full surface area, at least from the carrying seam 3 to the suspension point 4, with a dissipative or conductive material in a surface resistance range, measured in accordance with trbs 2153, of 0.1 to 108 ohms.. . ... Bayer Aktiengesellschaft

Reaction chamber for a chemical reactor, and chemical reactor constructed therefrom

A reaction chamber for a chemical reactor comprises a casing (100) of the reaction chamber, a floor (200) of the reaction chamber having an opening (300) located in the floor, an agitator shaft (400) located in the chamber and having at least one agitator element (500), connected thereto, wherein the agitator shaft (400), seen in the longitudinal direction, has a beginning (600) and an end (700). In the opening (300) of the floor (200) a removable sleeve (800) is provided, which projects out of the reaction chamber. ... Bayer Aktiengesellschaft

Multi-stage stirred reactor having reduced back mixing

The present invention relates to a multistage stirred reactor, comprising a multiplicity of mutually adjacent reaction chambers and stirring elements for mixing the contents of at least one of the reaction chambers, wherein, between adjacent reaction chambers, there is in each case provided at least one opening that can be closed by means of closure means, such that in the open state there is a fluidic connection between the adjacent reaction chambers and in the closed state the adjacent reaction chambers are separated from one another. At least one of the closure means (300, 310, 320) is connected to an actuation rod (500, 510, 520) that is guided out of the stirred reactor. ... Bayer Aktiengesellschaft

03/02/17 / #20170056825

Ultrafiltration unit for continuous buffer or medium exchange from a protein solution

The invention relates to an ultrafiltration unit for continuous buffer or medium exchange, a method for continuous buffer or medium exchange in the ultrafiltration unit, and a plant in particular for (semi)continuous production of biopharmaceutical and biological macromolecular products in particular, such as proteins, e.g. Monoclonal antibodies and vaccines, comprising the ultrafiltration unit according to the invention.. ... Bayer Aktiengesellschaft








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Bayer Aktiengesellschaft in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Bayer Aktiengesellschaft with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###